SCHEMBL1253404

SCHEMBL1253404

Cc1cccc2c1c(C(N)=O)c(C(N)=O)n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.42
SRC P12931 1/20 0.42
SLC9A1 P19634 1/20 0.40
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
IDO1 P14902 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
MDM2 Q00987 1/20 0.37
MCL1 Q07820 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PARP1 P09874 2/20 0.36
EPHB4 P54760 2/20 0.35
TSHR P16473 2/20 0.35
KDM4E B2RXH2 2/20 0.35
BRD4 O60885 1/20 0.35
BRPF1 P55201 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1504224 0.98 EGFR (0.41) EGFRSRCSLC9A1ALDH1A1MAPT
SCHEMBL28434877 0.85 SLC9A1 (0.41) EGFRSRCSLC9A1ALDH1A1MAPT
SCHEMBL28268477 0.85 EGFR (0.43) EGFRSRCSLC9A1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL28263963 0.84 SLC9A1 (0.40) EGFRSRCSLC9A1ALDH1A1MAPT
SCHEMBL2662182 0.84 SLC9A1 (0.40) EGFRSRCSLC9A1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL28262770 0.84 SLC9A1 (0.40) EGFRSRCSLC9A1ALDH1A1MAPT
SCHEMBL5799161 0.79 EGFR (0.41) EGFRALDH1A1MAPTLMNAPKM
SCHEMBL4782813 0.76 PLA2G2A (0.45) SLC9A1ALDH1A1MAPTLMNAPKM
SCHEMBL27798472 0.73 EGFR (0.41) EGFRALDH1A1MAPTLMNAPKM
SCHEMBL369886 0.73 BAZ2B (0.42) EGFRSRCALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 US disclosed
US-7880005-B2 reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID PAH, CA4, TET2 EGFR 3159/4885SRC 2091/4885SLC9A1 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.